《金沙娱城总站3777》官方网站

20

您的位置:首页 > 金沙娱城总站3777 > 2016年 > 2期

二甲双胍对2型糖尿病患者尿MCP-1排泄的影响

来自:金沙娱城总站3777  编辑:戴晓康 邢燕 叶山东|点击数:|2016-03-06

 

    【摘要】  目的    观察二甲双胍(Met)对T2DM患者尿单核细胞趋化蛋-1(MCP-1)排泄的影响,探讨其肾脏保护作用。 方法 121例T2DM患者(T2DM组)根据抗糖尿病治疗方案分为胰岛素治疗(Ins)治疗组和磺脲类治疗(SUs)治疗组,上述两组再根据分别分为Ins治疗亚组和Ins联合Met治疗亚组,以及SUs 治疗亚组和SUs联合Met治疗亚组,另选择24名健康对照(NGT) 组,比较各组FPG、2 hPG、HbA1c、UACR和尿MCP-1/肌酐比(UMCR)等指标。  结果   与NC组比较,T2DM组FPG [(4.85±0.10) vs (7.21±0.14) mmol/L]、2 hPG [(5.24±0.22) vs (9.71±0.31) mmol/L]、HbA1c[(5.22±0.06) % vs (7.03±0.10)%]、尿白蛋白/肌酐(UAlb/Cr) [(13.63±1.03) vs (27.68±3.99)mg/g]和UMCR [(30.71±1.83) vs (95.96±17.10)pg/ng]升高(P<0.05);与Ins治疗亚组比较,Ins联合Met治疗亚组UACR[(42.96±6.24) vs (10.48±1.98)mg/g]和UMCR[(116.2±10.47) vs (27.42±4.45)pg/ng]降低(P<0.05);与SUs 治疗亚组比较,SUs联合Met治疗亚组UACR [(52.43±7.80) vs (18.31±5.70)mg/g]和UMCR [(240.8±12.77) vs (53.58±8.11) pg/ng]降低 (P<0.05)。相关分析显示,T2DM患者UMCR与UACR呈正相关(r=0.79, P<0.01)。 结论   Met可减少T2DM患者尿MCP-1的排泄,该作用可能与其肾脏保护有关。

    【关键词】  二甲双胍;糖尿病,2型;糖尿病肾病;单核细胞趋化蛋-1

   The effect of Metformin on urinary MCP-1 excretion in patients with type 2 Diabetes 

  【AbstractObjective  To investigate the effect of Metformin on urinary MCP-1 excretion in patients with T2DM and explore its possible reno-protective mechanisms.  Methods  A total of 121 T2DM patients were enrolled in this study and divided into two groups: insulin treatment group and sulfonylurea treatment group. Then the two groups were further divided into four subgroups according to combination of Metformin: Ins-I(insulin only)Ins-II (insuin+Met), SUs-I(SUs only) and SUs -II(SUs +Met) subgroup. Healthy subjects were selected as the normal control group (NC group, n=24).FPG,2 hPG,HbA1c, urinary albumin to creatinine(UACR) and urinary MCP-1 to creatinine (UMCR) were measured in all subjects.  Results  FPG [4.85±0.10vs (7.21±0.14) mmol/L], 2 hPG [5.24±0.22vs (9.71±0.31) mmol/L], HbA1c[5.22±0.06vs (7.03±0.10) %], UACR [13.63±1.03vs (27.68±3.99) mg/g]and UMCR [30.71±1.83vs (95.96±17.10) pg/ng] were all increased in T2DM patients than in NC group(P<0.05). UACR(10.48±1.98)vs(42.96±6.24) mg/g and UMCR(27.42±4.45vs116.2±10.47)pg/ng were significantly decreased in Ins-II group than in Ins-I group(P<0.05). UACR(18.31±5.70,52.43±7.80)mg/g and UMCR(53.58±8.11, 240.8±12.77)pg/ng were significantly decreased in SUs-II group than in SUs-I group. UMCR was positively associated with UACR in T2DM patients (r=0.79,P<0.01). Conclusion  Metformin can reduce the excretion of urinary MCP-1 inpatients with T2DM. This may be associated with its reno-protective effect.

Key wordsMetformin; Diabetes mellitus,type 2;Diabetic nephrophyDN; Monocyte chemotactic

 

上一篇:血清糖化终末产物类物质与糖尿病慢性肾脏疾病的关系 下一篇:应用动态血糖监测系统评估糖尿病合并不同阶段的慢性肾功能不全患者糖化血红蛋白及糖化白蛋白准确性的研究